

## Evrysdi

Qatar · access guide

# How to access Evrysdi from Qatar, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Qatar patient, infant, child, or adult, with spinal muscular atrophy (SMA) confirmed by biallelic SMN1 mutations may receive a prescription for Evrysdi (risdiplam) from their treating neurologist. Evrysdi is FDA-approved, developed by Roche and Genentech with PTC Therapeutics and the SMA Foundation, and is an oral once-daily liquid SMN2 splicing modifier. Evrysdi is available in some Qatar tertiary centres; where your specific centre does not stock it or where supply is inconsistent, the named-patient pathway is a legitimate bridge.

This guide explains how Reserve Meds supports access in the formulary-gap scenario and where we fit in.

## The clinical situation

Evrysdi is a once-daily oral liquid (or gastrostomy-tube-administered) SMN2 splicing modifier. Weight-based dosing covers paediatric and adult regimens. Eligibility anchors to SMN1 biallelic mutation confirmation and clinical or pre-symptomatic SMA. Baseline assessment is modest compared with gene-therapy or intrathecal regimens. Your neurology team will confirm genotype and plan the monitoring cadence. Because administration is oral, families avoid the logistics of intrathecal visits, a meaningful consideration in Qatar where patient travel between regional centres and tertiary neurology units can be substantial.

## Is Evrysdi legally importable into Qatar?

Yes, via the Qatar Ministry of Public Health (MOPH) named-patient import framework. The mechanism permits a MOPH-licensed physician to import a medicine not locally registered, or not routinely stocked at a given institution, when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is available for the patient, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented.

## How the pathway works, step by step

---

1. **Consultation with your neurologist.** SMN1 confirmation, clinical SMA type, weight documentation, baseline functional assessment, clinical rationale letter.
2. **Weight-based dosing plan.** The prescribing neurologist confirms the regimen.
3. **MOPH named-patient application.** Your physician files the dossier including rationale, patient reference, and dosing plan.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Evrysdi from the manufacturer's authorised distribution chain under DSCSA.
5. **Controlled shipment.** Evrysdi ships with appropriate refrigerated logistics and full chain-of-custody documentation to the importer of record.
6. **Initiation and ongoing refill cadence.** Your team initiates daily dosing, monitors motor function and routine safety, and plans refill cycles.

## What documentation your physician needs

---

- Clinical rationale letter confirming SMA diagnosis, SMN1 biallelic status, clinical SMA type, weight, and Evrysdi as the indicated therapy
- Verification of SCFHS medical licence
- SMN1 molecular-testing report
- Weight-based dosing plan
- Multi-month refill schedule

Reserve Meds provides a physician documentation kit bundling the MOPH templates reviewers expect to see for SMA named-patient files.

## Costs and timing

---

Evrysdi's US cash-pay drug-only reference cost is weight-based. In an indicative 2026 drug-only range (delivered quote issued at intake), annual cost for a paediatric patient sits near USD 100,000-340,000 depending on weight, and for an adult patient near USD 340,000. International logistics, MOPH documentation handling, importer-of-record fees, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.

Indicative timing for first dispensation after cohort intake opens is 7-14 days from the moment a complete MOPH application is submitted.

*Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.*

A culturally-aware note: SMA prevalence in Qatar is elevated by consanguinity and multiple affected children in one extended family is not uncommon. Our case-lead structure supports family-level continuity while each individual case is reviewed on its clinical merits.

## Reserve Meds's role

---

- **Sourcing.** Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- **Documentation.** Regulatory package for your physician and MOPH review, keyed to the SMA rationale.
- **Logistics.** Refrigerated shipment to the nominated pharmacy with importer-of-record handling.
- **Concierge case lead.** A named point of contact supporting the multi-year daily-dosing treatment horizon and ongoing refill cycles.

**What we do not do:** we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

## Frequently asked

---

**How does Evrysdi compare with Spinraza?** Evrysdi is daily oral; Spinraza is every-four-month intrathecal. Both address the SMN pathway. Your neurologist selects based on anatomy, caregiver preference, and clinical picture.

**Can Evrysdi follow Zolgensma?** Sequential therapy is not a contraindication; some families use add-on Evrysdi after gene therapy. Your neurologist decides.

**How is the liquid stored?** Refrigerated at the pharmacy and during shipment; a room-temperature in-use stability window applies once reconstituted, your pharmacy and family will manage.

**Will insurance or MoH cover this?** Cash-pay is the default for named-patient imports. Some Qatar private insurers and MoH rare-disease channels consider case-by-case reimbursement; we supply documentation but do not process claims directly.

### *Reserve Meds's role*

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### Reserve Meds

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com